Gilead Sciences (GILD) just got a confidence boost from Wall Street, with Truist initiating coverage at Buy and Mizuho ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from the trial at a future science congress and submit applications to health ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug Biktarvy in a late-stage study involving previously untreated adult ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read more on GILD stock here.

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval molecule as a new anchor treatment for the infectious disease. Integrase strand ...

Bristol Myers Squibb BMY and Gilead Sciences, Inc. GILD are leading biotechnology companies with broad, diverse portfolios ...

Evercore 8th Annual Healthcare Conference December 3, 2025 10:50 AM ESTCompany ParticipantsDietmar Berger - Chief ...

In 2024, over half of patients found to have HIV in Europe received a late diagnosis, which is often associated with poor ...

Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best slow growth stocks to invest in. On November 21, Mizuho increased ...

HIV treatment has significantly evolved over the past 30 years, transforming HIV from a fatal disease to a manageable chronic ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal double-blind Phase 3 trial of the ...

A 42-year-old man presented to the emergency department with complaints of difficulty ambulating, fatigue, unintentional weight loss and progressively worsening near vision.His medical history was ...